Fig. 1

A The expression of TACR2 in all cancers was obtained using the TIMER database. Among them, in kidney chromophobe, kidney renal clear cell carcinoma, and kidney papillary cell carcinoma (KIRP), the expression levels of TACR2 in tumor tissues were lower than that in normal tissues P values were all lower than 0.05, suggesting statistically significant results. B Pair design was performed in TCGA-PRAD to calculate the expression of TACR2 in tumor tissues and normal tissues of the same patient (P = 1.341e−06). C The expression of TACR2 in tumor tissues and normal tissues of different patients was calculated by randomization in TCGA-PRAD (P = 1.192e−12). D Expression of TACR2 in the three clinical stages of PRAD (P = 5.401e−05). E The expression of TACR2 in different Gleason score groups of PRAD (P = 4.441e−07). F Survival analysis of the group with high expression of TACR2 and the group with low expression of TACR2 showed that the group's survival rate with high expression of TACR2 was higher (P = 0.0004, HR = 0.5302). G In GSE46602, TACR2 is enriched in the B cell receptor signaling pathway, cancer pathways, the T cell receptor signaling pathway, and the Wnt signaling pathway